GlassScriptPhysician profile
Garrett Mccoy
NPI 1720510548
$4,251.13
in general payments reported to CMS, 2019-2025
23 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $69.95 · 2021: $399 · 2022: $1,967 · 2023: $827 · 2024: $463 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.48 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.89 | 2022-2025 | |
| Janssen Biotech, INC. | $744.77 | 2021-2025 | Tremfya |
| Incyte Corporation | $451.59 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $330.41 | 2021-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $269.33 | 2022-2024 | Puraply |
| Ucb, INC. | $238.28 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $215.50 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Biofrontera INC. | $186.50 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $179.41 | 2022 | |
| Sun Pharmaceutical Industries INC. | $170.11 | 2021-2025 | Ilumya |
| Amgen INC. | $150.29 | 2021-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.35 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.73 | 2022-2023 | |
| Kerecis Limited | $67.40 | 2022 | |
| Genzyme Corporation | $27.77 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.75 | 2025 | Vtama |
| Kyowa Kirin, INC. | $21.49 | 2025 | |
| Convatec INC. | $20.91 | 2023 | |
| Pfizer INC. | $17.71 | 2023 | |
| Mimedx Group, INC. | $17.09 | 2024 | |
| Almirall LLC | $14.86 | 2022 | |
| Tactile Systems Technology INC | $14.16 | 2022 | |
| Nabriva Therapeutics, Plc | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.